| Discovery of serum proteomic biomarkers for prediction of response to infliximab (a monoclonal anti-TNF antibody) treatment in Rheumatoid Arthritis: an exploratory analysis I Ortea, B Roschitzki, JG Ovalles, JL Longo, I de la Torre, I González, ... Journal of Proteomics, 2012 | 51 | 2012 |
| Independent candidate serum protein biomarkers of response to adalimumab and to infliximab in rheumatoid arthritis: an exploratory study I Ortea, B Roschitzki, R López-Rodríguez, EG Tomero, JG Ovalles, ... PLoS One 11 (4), e0153140, 2016 | 25 | 2016 |
| Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality L Riancho-Zarrabeitia, V Martínez-Taboada, I Rúa-Figueroa, F Alonso, ... Lupus 29 (12), 1556-1565, 2020 | 24 | 2020 |
| Hormonal dependence and cancer in systemic lupus erythematosus T Cobo‐Ibáñez, A Urruticoechea‐Arana, I Rúa‐Figueroa, ... Arthritis Care & Research 72 (2), 216-224, 2020 | 12 | 2020 |
| Associated factors to serious infections in a large cohort of juvenile-onset systemic lupus erythematosus from Lupus Registry (RELESSER). V Torrente-Segarra, TC Salman-Monte, Í Rúa-Figueroa, V Del Campo, ... Seminars in Arthritis and Rheumatism 50 (4), 657-662, 2020 | 8 | 2020 |
| Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients? L Riancho-Zarrabeitia, VM Martínez-Taboada, I Rúa-Figueroa, F Alonso, ... Clinical and Experimental Rheumatology 39 (3), 555-563, 2020 | 5 | 2020 |
| Clinical and therapeutic management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: RADAR study A Gomez-Centeno, E Rubio-Romero, JG Ovalles, S Manrique-Arija, ... Rheumatology International 39, 2015-2024, 2019 | 3 | 2019 |
| OP0249 ANTIPHOSPHOLIPID SYNDROME (APS) IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) LEADS TO A MORE SEVERE DISEASE L Riancho-Zarrabeitia, VM Taboada, I Rua-Figueroa, F Sánchez-Alonso, ... Annals of the Rheumatic Diseases 78 (Suppl 2), 204-205, 2019 | 1 | 2019 |
| OP0124 DO ALL ANTIPHOSPHOLIPID ANTIBODIES CONFER THE SAME RISK FOR MAJOR ORGAN INVOLVEMENT IN SLE PATIENTS? L Riancho-Zarrabeitia, VM Taboada, I Rua-Figueroa, F Sánchez-Alonso, ... Annals of the Rheumatic Diseases 78 (Suppl 2), 136-137, 2019 | 1 | 2019 |
| Thromboelastometry shows a prothrombotic state in systemic lupus erythematosus related to diminished fibrinolysis and microparticle-derived tissue factor IF Bello, FJL Longo, VJ Yuste, M Canales, J Ovalles, N Butta Blood 126 (23), 2317, 2015 | 1 | 2015 |
| AB0520 evaluating the effect of belimumab on clinical disease activity and B-cell in patients with systemic lupus erythematosus D Hernandez-Flόrez, L Valor, T Del Río, JC Nieto, J Martinez, J Ovalles, ... Annals of the Rheumatic Diseases 74 (Suppl 2), 1074-1074, 2015 | 1 | 2015 |
| Relationship between age of onset and clinical profile in systemic lupus erythematosus patients J Martinez-Barrio, JG Ovalles, FJ Lopez-Longo, I de la Torre, ... Arthritis and Rheumatism 63 (10), S553-S554, 2011 | 1 | 2011 |
| AB0506 GIANT CELL ARTERITIS: IS ROUTINE CLINICAL PRACTICE COMPREHENSIVE ENOUGH? J Martínez-Barrio, BS Benavente, TDR Blasco, A Ariza, J Ovalles, ... Annals of the Rheumatic Diseases 79 (Suppl 1), 1551-1551, 2020 | | 2020 |
| POLYAUTOIMMUNITY IN SYSTEMIC LUPUS ERYTHEMATOSUS. DATA FROM A LARGE SPANISH COHORT: SPANISH SOCIETY OF RHEUMATOLOGY REGISTRY OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS … N Mena-Vazquez, A Fernandez-Nebro, I Rua-Figueroa, ... ANNALS OF THE RHEUMATIC DISEASES 78, 1174-1174, 2019 | | 2019 |
| PATIENT ACCEPTABLE SYMPTOMS STATE (PASS) QUESTIONNAIRE APPLICATION IN THE COHORT OF SLE PATIENTS FROM THE SPANISH SOCIETY OF RHEUMATOLOGY (RELESSER): ASSOCIATION WITH ACTIVITY … T Vazquez Rodriguez, I Rua Figueroa, V Del Campo Perez, J Narvaez, ... ANNALS OF THE RHEUMATIC DISEASES 78, 420-420, 2019 | | 2019 |
| THU0161 ORAL VERSUS SUBCUTANEOUS METHOTREXATE IN RECENTLYDIAGNOSED RHEUMATOID ARTHRITIS: DO WE GET THE SAME RESULTS? AMA Alfaro, LRC Motta, LAT Cid, CY Soleto, LT Folguera, KF Lopez, ... Annals of the Rheumatic Diseases 78 (Suppl 2), 353-354, 2019 | | 2019 |
| SAT0199 POLYAUTOIMMUNITY IN SYSTEMIC LUPUS ERYTHEMATOSUS. DATA FROM A LARGE SPANISH COHORT: SPANISH SOCIETY OF RHEUMATOLOGY REGISTRY OF PATIENTS WITH SYSTEMIC LUPUS … N Mena-Vázquez, A Fernandez-Nebro, I Rúa-Figueroa, ... Annals of the Rheumatic Diseases 78 (Suppl 2), 1174-1174, 2019 | | 2019 |
| AB1358-HPR SUICIDAL BEHAVIORS IN PATIENTS WITH INTRAVENOUS BIOLOGIC THERAPIES AL Esteban, RDG Benitez, AA Amigo, JCS Zanotti, FG Calle, JC Nieto, ... Annals of the Rheumatic Diseases 78 (Suppl 2), 2143-2143, 2019 | | 2019 |
| THU0283 PATIENT ACCEPTABLE SYMPTOMS STATE (PASS) QUESTIONNAIRE APPLICATION IN THE COHORT OF SLE PATIENTS FROM THE SPANISH SOCIETY OF RHEUMATOLOGY (RELESSER): ASSOCIATION WITH … TV Rodriguez, IR Figueroa, VDC Pérez, J Narváez, FJ López-Longo, ... Annals of the Rheumatic Diseases 78 (Suppl 2), 420-420, 2019 | | 2019 |
| 181 Associated factors to the presence of serious infections in a large cohort of juvenile-onset systemic lupus erythematosus JMP Reigosa, V Torrente-Segarra, VDC Perez, T Salman-Monte, ... Lupus Science & Medicine 6 (Suppl 1), 2019 | | 2019 |
